Show simple item record

dc.contributor.authorGriffiths, Richard W
dc.contributor.authorGilham, David E
dc.contributor.authorDangoor, Adam
dc.contributor.authorRamani, Vijay A C
dc.contributor.authorClarke, Noel W
dc.contributor.authorStern, Peter L
dc.contributor.authorHawkins, Robert E
dc.date.accessioned2009-08-10T17:21:39Z
dc.date.available2009-08-10T17:21:39Z
dc.date.issued2005-09-19
dc.identifier.citationExpression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. 2005, 93 (6):670-7 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid16222313
dc.identifier.doi10.1038/sj.bjc.6602776
dc.identifier.urihttp://hdl.handle.net/10541/76838
dc.description.abstractThe 5T4 oncofoetal antigen is a heavily glycosylated cell surface protein found on human placental trophoblast and on diverse types of human cancer but is not expressed at significant levels on adult human tissues in health. It therefore satisfies the criteria for a tumour-associated antigen and is an ideal target for the immunotherapy of cancer. We report here that 5T4 is strongly expressed on the majority of renal cell carcinomas and therefore this population of patients is suitable for trials of 5T4-targeted therapies. In particular, we have shown that T cells from renal cell carcinoma patients can be genetically modified to kill 5T4 expressing renal cancer cell lines by introduction of a chimeric-signalling protein. This protein consists of a single chain antibody fragment capable of binding antigen directly at the cell surface and then activating the T cell by virtue of a CD3zeta-signalling domain. This is a powerful tool that bypasses a number of mechanisms that allow tumours to escape T-cell killing and can be readily scaled up for clinical use.
dc.language.isoenen
dc.subjectRenal Canceren
dc.subjectKidney Canceren
dc.subject.meshAdenocarcinoma, Clear Cell
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntigens, Neoplasm
dc.subject.meshApoptosis
dc.subject.meshCarcinoma, Papillary
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshChromium
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshFemale
dc.subject.meshFlow Cytometry
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshInterferon-gamma
dc.subject.meshKidney Neoplasms
dc.subject.meshMale
dc.subject.meshMembrane Glycoproteins
dc.subject.meshMiddle Aged
dc.subject.meshT-Lymphocytes
dc.titleExpression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Paterson Institute for Cancer Research, Christie Research Centre, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe 5T4 oncofoetal antigen is a heavily glycosylated cell surface protein found on human placental trophoblast and on diverse types of human cancer but is not expressed at significant levels on adult human tissues in health. It therefore satisfies the criteria for a tumour-associated antigen and is an ideal target for the immunotherapy of cancer. We report here that 5T4 is strongly expressed on the majority of renal cell carcinomas and therefore this population of patients is suitable for trials of 5T4-targeted therapies. In particular, we have shown that T cells from renal cell carcinoma patients can be genetically modified to kill 5T4 expressing renal cancer cell lines by introduction of a chimeric-signalling protein. This protein consists of a single chain antibody fragment capable of binding antigen directly at the cell surface and then activating the T cell by virtue of a CD3zeta-signalling domain. This is a powerful tool that bypasses a number of mechanisms that allow tumours to escape T-cell killing and can be readily scaled up for clinical use.


This item appears in the following Collection(s)

Show simple item record